Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to further develop and test the Momentary Self-Monitoring and Feedback + Motivational Enhancement Therapy (MOMENT) intervention, a real-time, contextual intervention to reduce marijuana use among primary care patients.


Clinical Trial Description

This study proposes a pilot randomized trial to further develop and test the Momentary Self-Monitoring and Feedback + Motivational Enhancement Therapy (MOMENT) intervention, a real-time, contextual intervention to reduce marijuana use over three months in 15-to-24-year-old primary care patients who use frequently. We will randomize youth to one of two arms (goal 30 per arm completing 3-month follow-up): 1) MOMENT (MET + momentary self-monitoring + context-dependent feedback), or 2) MET-only. The two study arms will permit evaluation of the contributions of the self-monitoring and feedback components of the intervention above-and-beyond the MET and directly test the influence of the intervention on the link between momentary context and marijuana-related outcomes.

The specific aims of the study are

Specific Aim 1: Continued Feasibility Evaluation. In our preliminary work, we demonstrated that 1) youth perceive MOMENT to be easy to understand, comfortable, motivating, and helpful in reducing their marijuana use, 2) we can recruit 4 participants/month (minimum rate for the proposed study), and 3) we can successfully implement a MOMENT intervention study in the proposed recruitment sites. Based on this work, we have identified additional areas of feasibility on which to focus in the proposed study. Specifically, we aim to achieve:

1a. A signal response rate of at least 70% during each of three periods of momentary data collection - baseline, intervention, and 3-month follow-up.

1b. A diary response rate of at least 70% during each momentary data collection period

1. c. A retention rate of at least 80% of participants at the 3-month follow-up.

Specific Aim 2. Early-Stage Efficacy Exploration. Our preliminary work showed that both momentary and individual-level outcomes improved from baseline to three months post-intervention. The primary momentary outcomes are desire to use marijuana when in a triggering context and likelihood of use following exposure to a triggering context. The primary individual-level outcomes are number of use events/week, 30-day percent of days abstinent, dose/use event, and measures of motivation (importance of, readiness for, and confidence about reducing use). Based on the preliminary findings, we will explore these early-stage efficacy questions:

2. a. Will improvements in momentary outcomes be observed with MOMENT, but not MET-only?

(1) The association between exposure to self-identified trigger contexts and momentary desire to use marijuana will be attenuated at three months, compared to pre-intervention.

(2) The likelihood of marijuana use following exposure to a trigger context will be reduced at three months.

2b. Will improvements in individual-level outcomes be greater with MOMENT vs. MET-only?

1. The reduction in marijuana use frequency (events/week and 30-day percent of days abstinent) and dose (per use event) will be greater at three months.

2. The increase in motivation to reduce or discontinue use will be greater at three months. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01762696
Study type Interventional
Source Boston Children’s Hospital
Contact
Status Completed
Phase N/A
Start date May 2013
Completion date May 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT00158249 - Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals Phase 2
Completed NCT00842985 - Dronabinol Interactions in Humans N/A
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00227903 - Therapeutic Substance Abuse Treatment in Pregnancy - 1 Phase 2
Completed NCT00218478 - Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1 Phase 1
Completed NCT00227864 - A Brief Marijuana Intervention for Adolescent Women - 1 Phase 3
Completed NCT00249509 - Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals Phase 2
Completed NCT03717272 - Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects Phase 2
Completed NCT00142961 - Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Phase 2
Terminated NCT02102230 - CBT-I for Cannabis Use N/A
Completed NCT00580671 - Treatment for Adolescent Marijuana Abuse N/A
Completed NCT00360269 - Atomoxetine Treatment for ADHD and Marijuana Dependence Phase 2
Completed NCT00227916 - Motivational Interviews for Incarcerated Teens - 1 N/A
Completed NCT03154567 - Effects of Stress and Drug-cue Exposure (SCM) Phase 1
Active, not recruiting NCT05322941 - Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) Phase 2
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT03154580 - Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users Phase 1
Completed NCT00218517 - Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1 Phase 2
Completed NCT00217971 - Dronabinol Treatment for Marijuana Addiction Phase 2